Antitumor Effects and Distribution of Adriamycin Incorporated into Hydroxyapatite Implants in a Cancer Rat Model Bearing Swarm Rat Chondrosarcoma

Keiko Yamamura, Takashi Osada, Toshitaka Nabeshima, Hisashi Iwata, Toshihisa Yotsuyanagi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We investigated the antitumor effects and tissue distribution of adriamycin (ADR) incorporated into a hydroxyapatite (HAP) bead in a cancer rat model bearing Swarm rat chondrosarcoma. The Porous HAP bead (8.48 mm in diameter, 531 ±0.7 mg in weight) was used as a model bone graft. One ADR-HAP bead (ADR 0.4 mg-6.0 mg/bead) was implanted s.c. into a Sprague-Dawley rat at 6 days postinoculation of Swarm rat chondrosarcoma. ADR-HAP beads showed strong antitumor activities in a dose dependent manner. The dose of 6.0 mg/bead showed the highest efficacy with no toxic death: It caused a 98% growth inhibition on Day 31 postinoculation and a survival advantage of a 339% increase in life span. After the implantation of the ADR-HAP bead (0.4 mg/bead/body) and the i.v. administration of an equal dose of free adriamycin, we determined the tissue distribution of ADR for up to 90 days. ADR-HAP bead implanted in the tumors released ADR over a 12-week period in the target area. The diffusion of the drug to other organs such as the heart and liver was very low compared with the tumors. The area under the ADR concentration-time curve (AUC) of the tumors was 181.6μg-day/g and 5.22μg*day/g after the implantation of the ADR-HAP bead and the i.v. administration of free ADR, respectively. The targeting index of the tumors, defined as the ratio of the AUC after the implantation of the ADR-HAP bead to that after administration of free ADR, was 34.8. The targeting indices of 0.16 and 0.17 for the heart and liver, respectively, indicate that the implantation of the ADR-HAP bead reduced delivery of ADR to these organs. These results demonstrate that this method of administration may be useful in delivering adjuvant chemotherapy in order to prevent local recurrence in the site of the bony defect after the surgical removal of bone tumors.

Original languageEnglish
Pages (from-to)433-438
Number of pages6
JournalThe Japanese Journal of Pharmacology
Volume66
Issue number4
DOIs
Publication statusPublished - 01-01-1994

Fingerprint

Chondrosarcoma
Durapatite
Doxorubicin
Neoplasms
Tissue Distribution
Area Under Curve
Bone and Bones
Poisons
Liver
Adjuvant Chemotherapy

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

@article{78a6b97e975c437aa88da1b6c319de4c,
title = "Antitumor Effects and Distribution of Adriamycin Incorporated into Hydroxyapatite Implants in a Cancer Rat Model Bearing Swarm Rat Chondrosarcoma",
abstract = "We investigated the antitumor effects and tissue distribution of adriamycin (ADR) incorporated into a hydroxyapatite (HAP) bead in a cancer rat model bearing Swarm rat chondrosarcoma. The Porous HAP bead (8.48 mm in diameter, 531 ±0.7 mg in weight) was used as a model bone graft. One ADR-HAP bead (ADR 0.4 mg-6.0 mg/bead) was implanted s.c. into a Sprague-Dawley rat at 6 days postinoculation of Swarm rat chondrosarcoma. ADR-HAP beads showed strong antitumor activities in a dose dependent manner. The dose of 6.0 mg/bead showed the highest efficacy with no toxic death: It caused a 98{\%} growth inhibition on Day 31 postinoculation and a survival advantage of a 339{\%} increase in life span. After the implantation of the ADR-HAP bead (0.4 mg/bead/body) and the i.v. administration of an equal dose of free adriamycin, we determined the tissue distribution of ADR for up to 90 days. ADR-HAP bead implanted in the tumors released ADR over a 12-week period in the target area. The diffusion of the drug to other organs such as the heart and liver was very low compared with the tumors. The area under the ADR concentration-time curve (AUC) of the tumors was 181.6μg-day/g and 5.22μg*day/g after the implantation of the ADR-HAP bead and the i.v. administration of free ADR, respectively. The targeting index of the tumors, defined as the ratio of the AUC after the implantation of the ADR-HAP bead to that after administration of free ADR, was 34.8. The targeting indices of 0.16 and 0.17 for the heart and liver, respectively, indicate that the implantation of the ADR-HAP bead reduced delivery of ADR to these organs. These results demonstrate that this method of administration may be useful in delivering adjuvant chemotherapy in order to prevent local recurrence in the site of the bony defect after the surgical removal of bone tumors.",
author = "Keiko Yamamura and Takashi Osada and Toshitaka Nabeshima and Hisashi Iwata and Toshihisa Yotsuyanagi",
year = "1994",
month = "1",
day = "1",
doi = "10.1254/jjp.66.433",
language = "English",
volume = "66",
pages = "433--438",
journal = "Japanese Journal of Pharmacology",
issn = "0021-5198",
publisher = "Japanese Pharmacological Society",
number = "4",

}

Antitumor Effects and Distribution of Adriamycin Incorporated into Hydroxyapatite Implants in a Cancer Rat Model Bearing Swarm Rat Chondrosarcoma. / Yamamura, Keiko; Osada, Takashi; Nabeshima, Toshitaka; Iwata, Hisashi; Yotsuyanagi, Toshihisa.

In: The Japanese Journal of Pharmacology, Vol. 66, No. 4, 01.01.1994, p. 433-438.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antitumor Effects and Distribution of Adriamycin Incorporated into Hydroxyapatite Implants in a Cancer Rat Model Bearing Swarm Rat Chondrosarcoma

AU - Yamamura, Keiko

AU - Osada, Takashi

AU - Nabeshima, Toshitaka

AU - Iwata, Hisashi

AU - Yotsuyanagi, Toshihisa

PY - 1994/1/1

Y1 - 1994/1/1

N2 - We investigated the antitumor effects and tissue distribution of adriamycin (ADR) incorporated into a hydroxyapatite (HAP) bead in a cancer rat model bearing Swarm rat chondrosarcoma. The Porous HAP bead (8.48 mm in diameter, 531 ±0.7 mg in weight) was used as a model bone graft. One ADR-HAP bead (ADR 0.4 mg-6.0 mg/bead) was implanted s.c. into a Sprague-Dawley rat at 6 days postinoculation of Swarm rat chondrosarcoma. ADR-HAP beads showed strong antitumor activities in a dose dependent manner. The dose of 6.0 mg/bead showed the highest efficacy with no toxic death: It caused a 98% growth inhibition on Day 31 postinoculation and a survival advantage of a 339% increase in life span. After the implantation of the ADR-HAP bead (0.4 mg/bead/body) and the i.v. administration of an equal dose of free adriamycin, we determined the tissue distribution of ADR for up to 90 days. ADR-HAP bead implanted in the tumors released ADR over a 12-week period in the target area. The diffusion of the drug to other organs such as the heart and liver was very low compared with the tumors. The area under the ADR concentration-time curve (AUC) of the tumors was 181.6μg-day/g and 5.22μg*day/g after the implantation of the ADR-HAP bead and the i.v. administration of free ADR, respectively. The targeting index of the tumors, defined as the ratio of the AUC after the implantation of the ADR-HAP bead to that after administration of free ADR, was 34.8. The targeting indices of 0.16 and 0.17 for the heart and liver, respectively, indicate that the implantation of the ADR-HAP bead reduced delivery of ADR to these organs. These results demonstrate that this method of administration may be useful in delivering adjuvant chemotherapy in order to prevent local recurrence in the site of the bony defect after the surgical removal of bone tumors.

AB - We investigated the antitumor effects and tissue distribution of adriamycin (ADR) incorporated into a hydroxyapatite (HAP) bead in a cancer rat model bearing Swarm rat chondrosarcoma. The Porous HAP bead (8.48 mm in diameter, 531 ±0.7 mg in weight) was used as a model bone graft. One ADR-HAP bead (ADR 0.4 mg-6.0 mg/bead) was implanted s.c. into a Sprague-Dawley rat at 6 days postinoculation of Swarm rat chondrosarcoma. ADR-HAP beads showed strong antitumor activities in a dose dependent manner. The dose of 6.0 mg/bead showed the highest efficacy with no toxic death: It caused a 98% growth inhibition on Day 31 postinoculation and a survival advantage of a 339% increase in life span. After the implantation of the ADR-HAP bead (0.4 mg/bead/body) and the i.v. administration of an equal dose of free adriamycin, we determined the tissue distribution of ADR for up to 90 days. ADR-HAP bead implanted in the tumors released ADR over a 12-week period in the target area. The diffusion of the drug to other organs such as the heart and liver was very low compared with the tumors. The area under the ADR concentration-time curve (AUC) of the tumors was 181.6μg-day/g and 5.22μg*day/g after the implantation of the ADR-HAP bead and the i.v. administration of free ADR, respectively. The targeting index of the tumors, defined as the ratio of the AUC after the implantation of the ADR-HAP bead to that after administration of free ADR, was 34.8. The targeting indices of 0.16 and 0.17 for the heart and liver, respectively, indicate that the implantation of the ADR-HAP bead reduced delivery of ADR to these organs. These results demonstrate that this method of administration may be useful in delivering adjuvant chemotherapy in order to prevent local recurrence in the site of the bony defect after the surgical removal of bone tumors.

UR - http://www.scopus.com/inward/record.url?scp=0028598491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028598491&partnerID=8YFLogxK

U2 - 10.1254/jjp.66.433

DO - 10.1254/jjp.66.433

M3 - Article

C2 - 7723219

AN - SCOPUS:0028598491

VL - 66

SP - 433

EP - 438

JO - Japanese Journal of Pharmacology

JF - Japanese Journal of Pharmacology

SN - 0021-5198

IS - 4

ER -